^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Selective serotonin reuptake inhibitor

    Related drugs:
    1m
    Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury (clinicaltrials.gov)
    P4, N=100, Recruiting, John D. Dingell VA Medical Center | Trial completion date: Jun 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    1m
    Inflammatory differences and differential response to minocycline augmentation in young adult patients with first-episode drug-naïve melancholic and non-melancholic major depressive disorder. (PubMed, Prog Neuropsychopharmacol Biol Psychiatry)
    Minocycline augmentation significantly improved anhedonia in patients with melancholic MDD. Reducing pro-inflammatory cytokines (especially IL-1β) may play an important role in the potential mechanism for efficacy.
    Clinical • Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL1B (Interleukin 1, beta)
    |
    minocycline
    1m
    Department of Defense PTSD Adaptive Platform Trial - Master Protocol (clinicaltrials.gov)
    P2, N=800, Suspended, Global Coalition for Adaptive Research | Recruiting --> Suspended
    Trial suspension
    |
    fluoxetine
    1m
    Efficacy and Safety of Probiotics for Anxiety Depression (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Moon (Guangzhou) Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Mar 2026 --> Jun 2026
    Enrollment open • Trial initiation date
    2ms
    Protective effects of Withania somnifera (Ashwagandha) against chronic unpredictable mild stress-induced testicular damage in adolescent rats. (PubMed, J Mol Histol)
    Mitigating testosterone depletion and strengthening anti-apoptotic defense mechanisms, Ashwagandha provides more comprehensive protection compared to Sertraline. These findings suggest that Ashwagandha may serve as a potential phytotherapeutic supportive agent in mitigating stress-induced damage within the testicular tissue.
    Preclinical • Journal • IO biomarker
    |
    BAX (BCL2-associated X protein) • MKI67 (Marker of proliferation Ki-67) • SIRT6 (Sirtuin 6)
    2ms
    Efficacy and Safety of Sertraline Combined With Lactobacillus Crispatus in Adolescents With Depression (clinicaltrials.gov)
    P2, N=60, Recruiting, First Affiliated Hospital of Chongqing Medical University | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    Citalopram enhances cisplatin-induced cytotoxicity in T24 bladder cancer cells: An in vitro study. (PubMed, Exp Mol Pathol)
    Citalopram has been shown to improve the efficacy of cisplatin in suppressing T24 bladder cancer cells in vitro.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • VEGFC (Vascular Endothelial Growth Factor C) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9) • SNAI1 (Snail Family Transcriptional Repressor 1) • SLC2A1 (Solute Carrier Family 2 Member 1)
    |
    cisplatin
    2ms
    Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression (clinicaltrials.gov)
    P2, N=120, Recruiting, First Affiliated Hospital of Chongqing Medical University
    New P2 trial
    2ms
    ESPRIT: sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 (clinicaltrials.gov)
    P3, N=160, Recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Not yet recruiting --> Recruiting | Initiation date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2027 --> Dec 2027
    Enrollment open • Trial initiation date • Trial primary completion date
    2ms
    A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD (clinicaltrials.gov)
    P4, N=304, Active, not recruiting, University of Pennsylvania | Trial completion date: Jul 2026 --> Nov 2026 | Trial primary completion date: Jul 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    2ms
    Pupillometry in Delayed Sleep Wake Phase Disorder (clinicaltrials.gov)
    P=N/A, N=220, Recruiting, Northwestern University | Trial primary completion date: Feb 2029 --> Jul 2029
    Trial primary completion date
    2ms
    A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia (clinicaltrials.gov)
    P4, N=1200, Recruiting, University of Pennsylvania | Not yet recruiting --> Recruiting
    Enrollment open